340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

Report: Patient Groups Mum on High Drug Costs


 

Print Article

February 23, 2017—Big Pharma pours so much money into patient advocacy groups that the dough renders them mute on the drug price issue, according to a trenchant piece in USAToday.

“The National Patient Advocate Foundation receives 60 percent of its $2 million budget from the pharmaceutical industry, while the Colon Cancer Alliance gets 15 percent of its $1.2 million budget,” says the publication. “Several other groups get up to 20 percent of their revenue from drug companies.”

And surprise, surprise: NPAF and CCA have been harsh critics of the 340B drug discount program.

We’ve highlighted these conflicts of interest before but the alarm can’t be sounded often enough. While there are natural reasons drug companies and disease advocacy groups work closely, the enormous money spent gives the industry a convenient check on organized patient criticism on nearly any issue.

That investment has paid off handsomely in the drug pricing fight now gripping Washington. Currently, insurance companies and health providers are facing off against Big Pharma with hardly a patient in sight. Some patient groups put drug costs far down the list of priorities. “NPAF’s 2015 data on calls from about 14,000 cancer patients shows transportation was the top concern, followed by hospital and doctor co-pays, rent and mortgages and then prescription co-pays,” says the USAToday story.

Such is the power of the drug industry, even as it stumbles consistently in its effort to counter public ire over astronomical prices.

For a more realistic view of the situation, a new report in the Journal Cancer indicates some patients are cutting corners on their own treatment to avoid high drug bills.

340B helps needy patients avoid these impossible situations. Each day, thousands of Americans receive free or discounted medications and clinical services thanks to the program.

Recent Articles

  • HRSA Still Plans to Start Enforcing New 340B Regulation on April 1
  • Big Pharma Plays the Blame Game on Drug Prices
  • Report: Patient Groups Mum on High Drug Costs

Follow us on Twitter

340B Health Follow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340BHealth
340bhealth 340B Health @340bhealth ·
4 Mar

.@ololhealth in #Louisiana used #340B savings to open an emergency department in an underserved part of its community to ensure patients had access to vital health services. Learn more: https://bit.ly/3ZWw4HF #HealthEquity #Protect340B

Reply on Twitter 1632071853442502656 Retweet on Twitter 1632071853442502656 2 Like on Twitter 1632071853442502656 5 Twitter 1632071853442502656
340bhealth 340B Health @340bhealth ·
3 Mar

.@Pfizer had record revenues of more than $100 billion in 2022, during the year the company imposed restrictions on #340B discounts. This boosted the company’s profits while harming safety-net hospitals' ability to care for patients. $PFE #Protect340B

Reply on Twitter 1631705288838631424 Retweet on Twitter 1631705288838631424 2 Like on Twitter 1631705288838631424 3 Twitter 1631705288838631424
340bhealth 340B Health @340bhealth ·
2 Mar

Due to drug company #340B restrictions, Cynthia Coffey’s patient had his out-of-pocket cost for #insulin jump from less than $10 to $191. The patient was unable to fill the drug was readmitted to the hospital within days. https://bit.ly/41xiBaG #Facesof340B #Protect340B

Reply on Twitter 1631422757685567492 Retweet on Twitter 1631422757685567492 Like on Twitter 1631422757685567492 2 Twitter 1631422757685567492
Load More

RSS 340B Informed

  • UPDATED: Drugmakers Cutting 340B Discounts Reported Record Revenues in 2021
  • For Patients, Symptoms of Drugmaker 340B Restrictions Include Shortness of Breath, Hospitalization
  • End to Medicare 340B Payment Cuts in Sight

Copyright © 2023 · 340B Health